Searchable abstracts of presentations at key conferences in endocrinology

ea0090p157 | Pituitary and Neuroendocrinology | ECE2023

Various cut-off points for paradoxical increase of growth hormone after glucose load in patients with acromegaly and their clinical implications

Godlewska Magdalena , Bogusławska Anna , Grochowska Anna , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: Paradoxical increase of growth hormone after glucose load (PR) and its clinical significance remain the focus of researchers. Different cut off points for diagnosis of PR are used in the literature. Aim : Our aim was to investigate 3 different definitions of PR and their clinical implications.Material and Methods: We analyzed 116 consecutive patients diagnosed with acromegaly in 2012-2022. We included 89 patients with...

ea0090p168 | Pituitary and Neuroendocrinology | ECE2023

Quantitative assessment of the signal intensity of somatotropin pituitary tumors and its clinical implications in consecutive newly-diagnosed patients with acromegaly

Godlewska Magdalena , Bogusławska Anna , Grochowska Anna , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: Somatotroph Pituitary Neuroendocrine Tumor’s (sPitNET) signal intensity in T2-weighted MR images (SI) was reported as prognostic marker for tumor’s aggressiveness and poor response to 1st generation somatostatin analogs (SSA). Tumors are arbitrary divided into 3 groups: hyperintensive (HYPER), isointensive (ISO) and hypointensive (HYPO). Aim: Our aim was to quantitatively assess SI of sPitNETs and investigate its clinic...

ea0090p169 | Pituitary and Neuroendocrinology | ECE2023

Lymphocytic Hypophysitis – many faces of the same disesase. Watchful waiting could be suggested therapeutic approach in majority of patients

Kluczyński Łukasz , Godlewska Magdalena , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: Clinical manifestation of hypophysitis depends on presence of hormonal abnormalities and/or enlargement of pituitary structures. Both the diagnosis and treatment still remain challenging. Hormonal replacement is the basic therapy, while steroids are the first-line treatment in case of mass related symptoms. The course of the disease varies from spontaneous remission to atrophy of the pituitary gland.Aim: To characterize and sum up clinical/...

ea0070aep599 | Pituitary and Neuroendocrinology | ECE2020

Midparental height is an important predictive parameter in a late diagnosis of acromegaly and gigantism in adults. Single centre, pilot study

Bogusławska Anna , Gilis-Januszewska Aleksandra , Godlewska Magdalena , Olszewska Marta , Hubalewska-Dydejczyk Alicja , Starzyk Jerzy

Introduction: Acromegaly is a rare disorder caused by excessive growth hormone production. Common clinical manifestations are visual changes as well as serious systemic complications. In childhood and adolescence, excessive growth hormone production leads to abnormal tall stature. To date, only a few studies have been published focusing on analysing the growth of patients with acromegaly, in particular regarding the growth of their parents and siblings. A&#...

ea0073aep472 | Pituitary and Neuroendocrinology | ECE2021

Age and sex differences among patients with acromegaly

Anna Boguslawska , Gilis-Januszewska Aleksandra , Godlewska Magdalena , Nowak Andrzej , Starzyk Jerzy , Hubalewska-Dydejczyk Alicja

IntroductionAcromegaly is a chronic, slowly progressing disease caused in most cases by growth hormone (GH)- producing pituitary neuroendocrine tumors (PitNETs). This rare disorder is associated with a spectrum of various clinical manifestations and treatment outcomes differ between patients. The aim of this study was to evaluate the impact of age at the onset of symptoms and sex on clinical features, comorbidities, biochemical status at the diagnosis, a...

ea0093oc25 | Oral communication 4: Pituitary and Neuroendocrinology | EYES2023

The genetic background of acromegaly in a tertiary referral centre in Krakow, Poland

Bogusławska Anna , Godlewska Magdalena , Rzepka Ewelina , Korbonits Marta , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: Acromegaly is the most genetically determined pituitary disease.Objectives: We studied the prevalence of syndromic disease and germline mutations (AIP, MEN1, GNAS, PRKAR1A, CDKN1b) in a cohort of unselected, consecutive patients with acromegaly.Materials and methods: A total of 133 patients (79 females, 54 males, age range 16–75 years) with somatotroph pituitary neuroendocrine tumor who were studied at t...

ea0081p690 | Pituitary and Neuroendocrinology | ECE2022

Clinical characteristics at diagnosis and diagnostic delay among newly-diagnosed patients with acromegaly- single-center, pilot study

Godlewska Magdalena , Bogusławska Anna , Kluczyński Łukasz , Rzepka Ewelina , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: Diagnostic delay remains significant among the patients with acromegaly, even though the disease awareness has improved over the years.Aim: The aim was to investigate the diagnostic delay and symptoms present at diagnosis of acromegaly among the newly-diagnosed patients.Material and methods: 72 consecutive patients diagnosed with acromegaly between 01.2014 and 12.2021 were evaluated. Division into groups based on: gen...

ea0081p693 | Pituitary and Neuroendocrinology | ECE2022

Multimodal treatment including temozolomide (TMZ) and pasireotide for aggressive, giant silent corticotroph PiTNET in a young patient

Bogusławska Anna , Kluczyński Łukasz , Godlewska Magdalena , Rzepka Ewelina , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Silent corticotroph pituitary neuroendocrine tumours (PiTNETs) are a subtype of nonfunctioning PiTNETs, that present positive immunostaining for adrenocorticotropin (ACTH) and/or show the expression of the transcription factor T-PIT without clinical signs of hypercortisolemia. They constitute 20% of all corticotroph PitNETs and manifest in most cases as macroadenoma with suprasellar extension and a higher tendency to apoplexy. We present a 33-year-old male with aggressive cour...

ea0081ep701 | Pituitary and Neuroendocrinology | ECE2022

Age at the diagnosis or age at the onset of symptoms- which should be taken into consideration in patients with early-onset acromegaly- pilot study

Godlewska Magdalena , Bogusławska Anna , Kluczyński Łukasz , Rzepka Ewelina , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: The group of young adults with acromegaly, despite initial reports about their aggressive course of disease, has not been thoroughly characterized. Aim: Our aim was to investigate the differences between the patients with early-onset acromegaly and with onset in older age. Material and methods: Consecutive patients diagnosed with acromegaly between 01.2014 and 12.2021 were included in this retrospective study, approve...

ea0081ep727 | Pituitary and Neuroendocrinology | ECE2022

Challenging management of giant prolactinomas in men: from efficient small dose of cabergoline to SSA, neurosurgery and Temozolomide

Gilis-Januszewska Aleksandra , Bogusławska Anna , Godlewska Magdalena , Kluczyński Łukasz , Hubalewska-Dydejczyk Alicja

Giant prolactinomas are very rare and constitute 2-3% of all lactotroph PitNETs with male preponderance. We present a case series of five male patients with giant prolactinomas with various clinical presentation. Case 1: A 66-year-old male hospitalized due to left peripheral facial palsy. In computer tomography (CT) pituitary mass (41 x 43 x 64 mm) invading cavernous/sphenoid sinuses/carotid arteries/optic chiasm was visualized. Bitemporal hemianopia/hea...